Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Glioblastoma

357 clinical trials

349 products

44 drugs

2 abstracts

Clinical trial
A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Status: Recruiting, Estimated PCD: 2025-03-01
Product
L19TNF
Product
Lomustine
Product
SurVaxM
Clinical trial
A Dose Optimization Study for L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
dabrafenib
Clinical trial
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Status: Recruiting, Estimated PCD: 2026-05-29
Product
PVSRIPO
Product
trametinib
Clinical trial
Phase Ib Study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children
Status: Completed, Estimated PCD: 2022-03-23
Clinical trial
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Status: Active (not recruiting), Estimated PCD: 2024-08-18
Clinical trial
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Status: Completed, Estimated PCD: 2021-08-23
Product
Vincristine
Clinical trial
A Phase 1 Study of TAS2940 in Patients With Locally Advanced or Metastatic Solid Tumors With EGFR and / or HER2 Aberrations
Status: Recruiting, Estimated PCD: 2025-05-01
Product
TAS2940
Product
MTX110
Clinical trial
Phase I Open Label Ascending Dose Study to Assess the Feasibility and Safety of Intermittent Infusions of MTX110 Administered by Convection-Enhanced Delivery (CED) in Patients With Recurrent Glioblastoma (rGBM) (MAGIC-G1)
Status: Active (not recruiting), Estimated PCD: 2028-08-31
Clinical trial
A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Azeliragon
Clinical trial
A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon Combined With Conventional Concurrent Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
ST101
Product
Dabrafenib
Product
Carboplatin
Clinical trial
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Temozolomide
Product
PRT3645
Clinical trial
A Phase I, Open Label, First In Humans (FIH), Single Dose Level Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
Status: Active (not recruiting), Estimated PCD: 2026-03-01
Product
ITI-1001
Product
Pemigatinib
Clinical trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)
Status: Active (not recruiting), Estimated PCD: 2024-11-29
Clinical trial
A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients With MGMT Unmethylated Glioblastoma
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for Resection
Status: Active (not recruiting), Estimated PCD: 2024-05-09
Product
CC-90010
Product
IGV-001
Clinical trial
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Placebo
Clinical trial
A Prospective, Open-Label, Single-Arm Pilot Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
Lumason
Product
Bevacizumab
Clinical trial
Assessment of Safety and Feasibility of Exablate Type 2 for Blood-Brain Barrier Disruption (BBBD) With Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-31
Product
ASC40
Clinical trial
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2025-06-30
Product
NMS-03305293
Product
MN-166
Clinical trial
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Treatment of Recurrent GBM With APG-157 Via Expanded Access
Status:
Product
APG-157
Clinical trial
Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
Status: Not yet recruiting, Estimated PCD: 2029-06-01
Product
Olutasidenib
Clinical trial
A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
TJ107
Product
BPM31510
Clinical trial
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Status: Recruiting, Estimated PCD: 2025-02-24
Product
ONC206
Clinical trial
A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Onfekafusp alfa
Clinical trial
A Study to Evaluate the Safety and Efficacy of Different Administration Sequences of L19TNF in Combination With Lomustine in Patients With Glioblastoma at First Progression
Status: Withdrawn, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Status: Completed, Estimated PCD: 2023-03-30
Product
Paxalisib
Product
Gallium Maltolate
Clinical trial
Expanded Access to Gallium Maltolate (GaM) for Adult Patients With Relapsed/Refractory Histologic or Molecular Glioblastoma
Status:
Product
RO7428731
Clinical trial
An Open-label, Multicenter, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Polio/Rhinovirus Recombinant
Clinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Irinotecan
Product
Lurbinectedin
Clinical trial
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Status: Terminated, Estimated PCD: 2018-09-14
Product
Enzastaurin
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1
Status: Completed, Estimated PCD: 2024-02-29
Clinical trial
Open-label Phase 2 Study of N-803 and PD-L1 t-haNK Combined With Bevacizumab in Subjects With Recurrent or Progressive Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2029-12-31
Product
PD-L1
Product
N-803
Product
LUM Imaging System
Clinical trial
Feasibility of the LUM Imaging System for In Vivo and Ex Vivo Detection of Cancer in Subjects With Low Grade Gliomas, Glioblastomas, and Cancer Metastases to the Brain
Status: , Estimated PCD: 2025-06-01
Product
OKN-007
Clinical trial
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled Adjuvant Trial in Newly Diagnosed Primary Glioblastoma Subjects to Assess the Efficacy and Safety of LAM561 in Combination With Radiotherapy and Temozolomide Standard of Care Treatment.
Status: Recruiting, Estimated PCD: 2024-10-15
Product
LAM561
Product
TMZ
Clinical trial
A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients With Surgically Resected Glioblastoma (GBM) or Astrocytoma With a Molecular Signature of Unmethylated Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2026-03-30
Product
CV09050101 mRNA vaccine
Clinical trial
An Interventional, Non-randomized, Phase 1/2, Light Dose-escalation Study to Investigate the Safety and Feasibility of Intraoperative Photodynamic Therapy (PDT) With Pentalafen® Drug and Heliance®Solution Device in Male and Female Patients 18 to 69 Years of Age With Grade IV Glioblastoma
Status: Recruiting, Estimated PCD: 2025-03-01
Product
5-ALA
Product
5-ALA HCl
Product
Belzutifan
Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Completed, Estimated PCD: 2020-06-16
Product
Chemotherapy
Product
Eflornithine
Clinical trial
An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Autologous genetically modified gamma-delta T cells
Product
Allogeneic genetically modified gamma-delta T cells
Product
BMX-001
Clinical trial
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Status: Active (not recruiting), Estimated PCD: 2023-08-17
Clinical trial
Phase 1 Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Effects of CM93 in Subjects With Recurrent Glioblastoma (rGBM) Characterized by Epidermal Growth Factor Receptor (EGFR) Mutation or Amplification
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Product
CTO
Product
Temodar
Clinical trial
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Status: Completed, Estimated PCD: 2019-09-12
Product
Epacadostat
Clinical trial
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2018-01-12
Product
CM93
Product
INO-9012
Product
Cemiplimab
Product
MDNA55
Product
INO-5401
Clinical trial
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Status: Terminated, Estimated PCD: 2022-06-03
Clinical trial
A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma
Status: Completed, Estimated PCD: 2018-10-09
Clinical trial
A Phase Ib/2 Open-label Study Investigating the Tolerability, Safety, Pharmacokinetic Properties and Efficacy of Oral OKN-007 in Participants With Recurrent High-grade Glioma
Status: Withdrawn, Estimated PCD: 2025-04-01
Product
BAL101553
Product
Nivolumab
Product
BBI608
Product
Pembrolizumab
Product
Lenvatinib
Product
PLB1001
Clinical trial
A Randomized, Controlled, Open, Multicenter, Phase II/III Clinical Study to Evaluate the Safety and Efficacy of Vebreltinib Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Status: Active (not recruiting), Estimated PCD: 2023-04-01
Product
Cisplatin + Etoposide
Clinical trial
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
Status: Active (not recruiting), Estimated PCD: 2024-12-20
Product
NGM707
Clinical trial
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma
Status: Withdrawn, Estimated PCD: 2024-02-01
Product
Selinexor
Product
SI-053
Product
CYNK-001
Clinical trial
A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas
Status: Recruiting, Estimated PCD: 2026-02-01
Product
EO2401
Product
Concurrent CRT Period
Product
Post-CRT Period
Product
Adjuvant Period
Product
OS2966
Clinical trial
A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 Using Convection-enhanced Delivery in Patients With Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection
Status: Terminated, Estimated PCD: 2023-02-27
Product
NUV-422
Clinical trial
An Open Label, Prospective, Pilot Study to Evaluate the Efficacy and Safety of Best Physician's Choice of Standard of Care Combined With NaviFUS System in Patients With Recurrent Glioblastoma Multiforme
Status: Completed, Estimated PCD: 2022-09-30
Product
hP1A8
Clinical trial
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Status: Terminated, Estimated PCD: 2022-08-31
Clinical trial
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Status: Terminated, Estimated PCD: 2020-01-23
Clinical trial
Randomized Phase 3 Trial of Standard Care Plus AV-GBM-1 vs Autologous Monocytes as Adjunctive Therapy Following Primary Surgery Plus Concurrent Radiation-temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2028-03-01
Clinical trial
An Open-label Dose Escalation Study to Estimate MTD, Identify DLTs and Study Pharmacokinetics Following a Single Dose of Intracranially Administered Temozolomide-based SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Gadoteridol
Clinical trial
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Status: Completed, Estimated PCD: 2022-04-04
Product
Depatuxizumab
Product
C5252
Clinical trial
A Phase 1B Study of the Safety of LAM561 Administered Orally in Combination With Temozolomide (TMZ) and Radiation Therapy or With TMZ Alone in the First Line Treatment of Subjects With Glioblastoma
Status: Completed, Estimated PCD: 2020-07-01
Product
Ad-RTS-hIL-12
Product
Veledimex
Clinical trial
A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo®) in Subjects With Recurrent or Progressive Glioblastoma
Status: Completed, Estimated PCD: 2021-08-05
Product
Cemiplimab-Rwlc
Clinical trial
A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2023-04-30
Clinical trial
A Phase 1b Dose Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Status: Terminated, Estimated PCD: 2022-11-04
Product
GX-I7
Product
Icapamespib
Clinical trial
Single-arm Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a 3-arm Expansion Group Including Fully Resected Patients and Combination With Bevacizumab or Pembrolizumab
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1b, Open-label, Dose-Finding Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-05-12
Product
NGM707 plus Pembrolizumab
Clinical trial
A Phase 2, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Product
AV-GBM-1
Product
Autologous monocytes
Product
Olaptesed pegol
Product
RSC-1255
Clinical trial
Oral ONC201 in Recurrent Glioblastoma, H3 K27M-mutant Glioma, and Diffuse Midline Glioma
Status: Active (not recruiting), Estimated PCD: 2023-08-01
Product
AVM0703
Clinical trial
AVM0703-EAP
Status:
Clinical trial
Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant Glioma
Status: Completed, Estimated PCD: 2017-06-27
Product
Hydrocortisone
Product
Proton pump inhibitor
Product
Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
Clinical trial
A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Standard Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2026-10-01
Product
ONC201
Clinical trial
A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients With Advanced Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2024-01-16
Clinical trial
An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene
Status: Active (not recruiting), Estimated PCD: 2021-11-22
Product
VXM01
Product
Avelumab
Product
5-Aminolevulinic acid
Clinical trial
An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery
Status: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
Evaluation of the Feasibility of PD L 506 for Stereotactic Interstitial Photodynamic Therapy (iPDT) in Adult Patients With Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)
Status: Completed, Estimated PCD: 2021-08-30
Product
DSP-7888
Product
lerapolturev
Clinical trial
A Phase 2, Open-label, Single-arm Study Evaluating the Efficacy, Safety and Tolerability of Lerapolturev (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Systemic Treatment
Product
pembrolizumab
Product
Ulixertinib
Clinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Status:
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Product
131I-IPA
Clinical trial
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2025-06-01
Product
LY2157299
Clinical trial
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2014-07-26
Clinical trial
A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2019-06-17
Clinical trial
Phase 2 Study of VAL-083 Treatment for MGMT Unmethylated Bevacizumab-naïve Glioblastoma in the Adjuvant or Recurrent Setting
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Product
VAL-083
Product
Ipilimumab
Clinical trial
Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)
Status: Recruiting, Estimated PCD: 2026-12-31
Product
TMZ
Clinical trial
GA-68 PSMA-11 PET To Evaluate Malignant Glioma Recurrence - A Pilot Study
Status: Not yet recruiting, Estimated PCD: 2026-04-30
Product
Ga 68 PSMA-11
Clinical trial
Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2025-07-01
Product
6-mercaptopurine
Clinical trial
INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs With GBM
Status: Recruiting, Estimated PCD: 2025-06-01
Product
CARv3-TEAM-E T cells
Clinical trial
I-ATTAC: Improved Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
Status: Terminated, Estimated PCD: 2023-02-10
Product
Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Product
Tetanus-Diphtheria Toxoid
Drug
GM-CSF
Product
111-Indium-labeling of Cells
Clinical trial
A Randomised Controlled Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Nabiximols
Clinical trial
A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
Status: Active (not recruiting), Estimated PCD: 2022-09-01
Clinical trial
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2019-10-23
Drug
Montanide ISA 51 VG
Product
Sargramostim
Product
SVN53-67/M57-KLH Peptide Vaccine
Clinical trial
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for Patients With MMP2+ Recurrent or Progressive Glioblastoma
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Chlorotoxin
Product
Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes
Clinical trial
Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)
Status: Not yet recruiting, Estimated PCD: 2027-05-31
Product
Gadolinium-Chelate
Clinical trial
Tofacitinib: Suppressing Tumor Invasion in Recurrent GBM Patients
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Tofacitinib
Clinical trial
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Status: Active (not recruiting), Estimated PCD: 2024-07-19
Drug
Atezolizumab
Product
Retifanlimab
Clinical trial
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Drug
temozolomide
Clinical trial
A Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemoradiation for the Adjuvant Treatment of Adult Glioblastoma
Status: Completed, Estimated PCD: 2023-12-01
Product
TH-1 Dendritic Cell Immunotherapy
Clinical trial
Phase 0 lead-in Trial of Pitavastatin in Primary and Recurrent Glioblastoma Patients
Status: Recruiting, Estimated PCD: 2024-05-01
Product
Pitavastatin
Clinical trial
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Status: Recruiting, Estimated PCD: 2027-06-30
Drug
Selinexor
Clinical trial
Phase 1 Study of Autologous Tris-CAR-T Cell Locoregional Immunotherapy for Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-11-01
Product
Inverse correlated dual-target truncated IL7Ra modified CAR-expressing autologous T-lymphocytes
Product
M032
Clinical trial
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Status: Terminated, Estimated PCD: 2022-04-30
Product
Regadenoson
Product
Regadensoson
Clinical trial
A Phase I Trial to Determine the Maximum Tolerated Dose and Patient-specific Dosimetry of Fractionated Intracavitary Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Lu-177 labeled 6A10-Fab-fragments
Clinical trial
A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination With Bevacizumab and Hypofractionated Radiotherapy in Patients With Recurrent GBM
Status: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Status: Active (not recruiting), Estimated PCD: 2024-06-14
Product
HER2(EQ)BBζ/CD19t+ T cells
Clinical trial
Phase Ib/II Multicentric Study Combining Glasdegib (PF-04449913) With Temozolomide in Patients With Newly Diagnosed Glioblastoma, Safety and Preliminary Efficacy for the Combination
Status: Completed, Estimated PCD: 2023-11-29
Product
PF-04449913
Clinical trial
Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2017-05-24
Clinical trial
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Product
Cediranib
Product
Olaparib
Clinical trial
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma
Status: Completed, Estimated PCD: 2022-09-30
Drug
Gemcitabine
Clinical trial
A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Sacituzumab Govitecan
Clinical trial
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma: Study Protocol for An International Multicenter Prospective Cohort Study (ENCRAM 2302)
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)
Status: Active (not recruiting), Estimated PCD: 2020-07-31
Drug
Poly-ICLC
Product
Peptides
Clinical trial
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2021-07-29
Drug
Adavosertib
Clinical trial
PNOC023: Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
Status: Recruiting, Estimated PCD: 2026-01-31
Drug
ONC206
Drug
ribociclib
Clinical trial
Phase I/II Study of Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Status: Recruiting, Estimated PCD: 2024-06-15
Clinical trial
Pilot Study of Subcutaneously Administered Natural Progesterone for the Treatment of Recurrent GBM
Status: Recruiting, Estimated PCD: 2025-08-25
Product
Therapeutic Progesterone
Clinical trial
RENEW: Pilot Study of Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
Status: Terminated, Estimated PCD: 2023-09-28
Product
Autologous DCs loaded with RNA encoding human CMV matrix protein pp65-flLAMP
Clinical trial
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Status: Completed, Estimated PCD: 2012-04-01
Product
F18-FPPRGD2
Drug
trametinib
Clinical trial
A Phase 1 Study of Tumor Treating Fields With 5 Day Hypofractionated Stereotactic Radiosurgery and Concurrent and Maintenance Temozolomide in Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2024-05-01
Product
Gadolinium
Clinical trial
Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)
Status: Completed, Estimated PCD: 2023-02-22
Product
APG101
Product
Alectinib
Product
Idasanutlin
Product
Vismodegib
Clinical trial
A Phase 1 and Randomized Phase 2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
Status: , Estimated PCD: 2026-06-30
Product
Temsirolimus
Product
Palbociclib
Clinical trial
Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
ruxolitinib
Drug
temozolomide
Clinical trial
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Status: Recruiting, Estimated PCD: 2026-07-31
Product
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine
Clinical trial
SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study
Status: Completed, Estimated PCD: 2021-04-21
Clinical trial
Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-09-10
Product
Abraxane
Clinical trial
A First-in-Human Clinical Trial of Pharmacologic Ascorbate and Ferumoxytol Combined With Concomitant Temozolomide and External Beam Radiation Therapy for Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Ferumoxytol
Product
Pharmacological ascorbate
Clinical trial
Phase III Trial of Temozolomide/Lomustine (TMZ/LOM) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT Promoter Methylated Glioblastoma (IDHwt) Patients +/- Tumor Treating Fields (Optune)
Status: Not yet recruiting, Estimated PCD: 2028-12-15
Clinical trial
Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma
Status: Recruiting, Estimated PCD: 2030-05-31
Product
Cyclophosphamide
Product
Fludarabine
Clinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2020-12-31
Product
Sapanisertib
Clinical trial
Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma
Status: Active (not recruiting), Estimated PCD: 2021-10-19
Product
Lapatinib
Clinical trial
ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2023-11-30
Product
pp65-shLAMP DC with GM-CSF
Product
unpulsed PBMC and saline
Product
Td
Product
Saline
Product
pp65-flLAMP DC
Clinical trial
A Phase 3, Open-label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2027-12-01
Product
Niraparib
Clinical trial
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Status: Completed, Estimated PCD: 2023-10-31
Product
BGB-290
Clinical trial
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
PEskE: A Phase 0/Surgical Window-of-opportunity Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Evolocumab in Patients With Recurrent High-grade Glioma or Glioblastoma
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Evolocumab
Clinical trial
A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas
Status: Recruiting, Estimated PCD: 2025-08-07
Product
Neural Stem Cells-expressing CRAd-S-pk7
Clinical trial
A Phase I Study of hEGFRvIII-CD3 Bi-scFv (BRiTE) in Patients With WHO Grade IV Malignant Glioma
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
hEGFRvIII-CD3
Clinical trial
Phase I/II Randomized Prospective Trial for Newly Diagnosed GBM, With Upfront Gross Total Resection, Gliadel®, Followed by Temodar® With Concurrent IMRT Versus GK
Status: Terminated, Estimated PCD: 2015-05-30
Clinical trial
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma (INTERROGATE-GBM)
Status: Not yet recruiting, Estimated PCD: 2024-09-01
Product
PEP-CMV vaccine
Clinical trial
Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
Status: Active (not recruiting), Estimated PCD: 2022-11-26
Clinical trial
Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors
Status: Completed, Estimated PCD: 2020-06-01
Clinical trial
Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Capecitabine
Clinical trial
An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide
Status: Completed, Estimated PCD: 2016-12-01
Product
Aldoxorubicin
Clinical trial
PhaseII Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed With HGG Including DIPG, Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways
Status: Not yet recruiting, Estimated PCD: 2028-05-30
Product
Ribociclib
Product
Everolimus
Clinical trial
Feasibility Pilot Study of OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Product
OKN 007
Clinical trial
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (Anti-PD-L1) in Combination With Cabozantinib in Patients With Recurrent Glioblastoma (rGBM)
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Cabozantinib
Clinical trial
Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG
Status: Recruiting, Estimated PCD: 2025-10-02
Product
Indoximod
Drug
cyclophosphamide
Product
Etoposide
Clinical trial
IIT2016-17-HU-KETORADTMZ: A Phase 1 Study of a 4-month Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Newly/Recently Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2021-09-03
Clinical trial
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2023-12-08
Drug
bevacizumab
Product
Microarray Analysis
Product
DNA methylation analysis
Clinical trial
A Phase Ib/II Randomized, Open Label Drug Repurposing Trial of Glutamate Signaling Inhibitors in Combination With Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2026-06-01
Product
Gabapentin
Product
Sulfasalazine
Product
Memantine
Clinical trial
A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2025-12-31
Product
RMC-5552
Clinical trial
A Pilot Study of Utility of 18F-FDOPA-PET for Neurosurgical Planning and Radiotherapy Target Delineation in Glioma Patients: Biopsy Validation of 18F-FDOPA-PET Uptake and Biodistribution in Brain Tumors
Status: Active (not recruiting), Estimated PCD: 2013-11-01
Product
Fluorine F 18 Fluorodopa
Clinical trial
A Phase I Study of RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
Status: Not yet recruiting, Estimated PCD: 2027-12-01
Product
pp65 RNA loaded lipid particles
Product
RNA loaded lipid particles, RNA-LPs
Clinical trial
A Multi-Arm, Open Label, Phase II Trial of WP1066 and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2027-12-27
Product
WP1066
Clinical trial
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2026-07-19
Clinical trial
Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Ibrutinib
Clinical trial
A Phase I Study of Metronomic Temozolomide and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma
Status: Terminated, Estimated PCD: 2015-08-20
Clinical trial
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
Status: Recruiting, Estimated PCD: 2025-04-30
Product
Cancer Personalized Profiling
Clinical trial
A Phase II, Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Imipramine
Clinical trial
A Target Validation/Phase1 Study of BGB-290 in Combination With Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase 0/I Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors
Status: Recruiting, Estimated PCD: 2028-02-01
Product
WSD0628
Clinical trial
A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Status: Active (not recruiting), Estimated PCD: 2015-11-30
Product
Ascorbate
Clinical trial
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Status: Terminated, Estimated PCD: 2022-04-30
Product
Encorafenib
Clinical trial
A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas
Status: Completed, Estimated PCD: 2020-12-31
Clinical trial
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)
Status: Recruiting, Estimated PCD: 2026-03-01
Drug
T-VEC
Clinical trial
Phase II Study of Short Course Hypofractionated Proton Beam Therapy Incorporating 18F-DOPA-PET/MRI for Elderly Patients With Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
A Phase I Lead-In to a 2x2x2 Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Product
Mefloquine
Drug
Metformin
Clinical trial
Clinical Study of Evaluating the Safety and Initial Efficacy of XS005 Cell Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma
Status: Recruiting, Estimated PCD: 2025-11-02
Product
XS005 Cell
Product
Temozolomide（TMZ）
Clinical trial
Phase 1, Dose Escalation, Non-Randomized, Open Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells (AMSCs) for Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2025-07-24
Product
Allogeneic Adipose-derived Mesenchymal Stem Cells
Clinical trial
A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Ad5-yCD/mutTKSR39rep-ADP
Clinical trial
An Open Label Phase 2 Study of Intravenously Administered Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Status: Recruiting, Estimated PCD: 2028-07-30
Product
Crizanlizumab-Tmca
Clinical trial
B-amyloid as a Marker for GBM Bioimaging
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Amyvid
Clinical trial
A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Product
Ramipril
Product
sonidegib
Clinical trial
Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-10-15
Product
Efineptakin alfa
Clinical trial
A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Gallium maltolate
Clinical trial
A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, and Efficacy of RZ-001 in Combination With Valganciclovir in Subjects With Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2029-03-01
Product
RZ-001
Product
VGCV
Clinical trial
A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2029-05-12
Product
Triapine
Drug
Filgrastim
Clinical trial
Phase 2 Study to Evaluate the Clinical Efficacy and Safety of Tislelizumab Plus Low-dose Bevacizumab in Bevacizumab Refractory Recurrent Glioblastoma With PTEN or TERT Gene Mutations
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Tislelizumab + Bevacizumab
Clinical trial
Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU
Status: Recruiting, Estimated PCD: 2025-12-20
Product
WSD0922-FU
Clinical trial
Phase I Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)
Status: Terminated, Estimated PCD: 2016-05-10
Clinical trial
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2022-08-23
Product
Marizomib
Clinical trial
A Phase I Study of Bevacizumab and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma
Status: Terminated, Estimated PCD: 2019-03-01
Clinical trial
A Phase I Study of [18F]DASA-23 as a PET Tracer for Evaluating Pyruvate Kinase M2 (PKM2) Expression in Healthy Volunteers and in Patients With Intracranial Tumors
Status: Completed, Estimated PCD: 2022-12-31
Product
Fluorine F 18 DASA-23
Clinical trial
A Phase 2 Trial of Paxalisib Combined With a Ketogenic Diet and Metformin for Newly Diagnosed and Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
E-SYNC T Cells
Clinical trial
Individualized Systems Medicine Strategy for Targeting Cancer Stem Cells in Patients With Recurrent Glioblastoma (ISM-GBM)
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Personalized drug combination
Clinical trial
A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
VB11
Clinical trial
A Phase 1 / 2 Study of Visudyne (Liposomal Verteporfin) in Persons With Recurrent High Grade EGFR-Mutated Glioblastoma
Status: Recruiting, Estimated PCD: 2025-08-15
Product
Verteporfin
Clinical trial
Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2027-07-01
Product
Afatinib
Clinical trial
Bortezomib Sensitization of Recurrent Grade-4 Glioma With Unmethylated MGMT Promoter to Temozolomide Phase 1B/II Study
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Bortezomib + Temozolomide
Product
Bortezomib and Temozolomide
Product
Dasatinib
Clinical trial
A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)
Status: Active (not recruiting), Estimated PCD: 2026-04-01
Drug
AN0025
Clinical trial
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Status: Recruiting, Estimated PCD: 2026-06-01
Drug
Regorafenib
Drug
VAL-083
Product
VT1021
Product
Troriluzole
Drug
ADI-PEG 20
Clinical trial
Stereotactic Accelerated Radiotherapy in GlioblastomA (SAGA)
Status: Recruiting, Estimated PCD: 2027-03-02
Product
Fluorodopa F 18
Clinical trial
Phase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma
Status: Recruiting, Estimated PCD: 2027-09-30
Product
Ad5-DNX-2401
Clinical trial
Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma
Status: , Estimated PCD: 2024-08-31
Clinical trial
Open Label Safety Study of Solriamfetol to Promote Wakefulness and Improve Cognition and Quality of Life in Patients With Primary Gliomas
Status: , Estimated PCD: 2024-07-01
Product
Soliramfetol
Clinical trial
Pilot Study of Anlotinib in Combination With STUPP Regimen for Treatment of Patients With Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2022-08-23
Product
Anlotinib
Product
G207
Clinical trial
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Status: Completed, Estimated PCD: 2022-04-30
Product
BMS 986016
Product
Anti-PD-1
Product
Anti-CD137
Clinical trial
A Phase II Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Terminated, Estimated PCD: 2023-05-02
Clinical trial
Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Dendritic Cell Tumor Cell Lysate Vaccine
Product
Poly ICLC
Clinical trial
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-09-29
Clinical trial
Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Randomized Phase 2 Clinical Trial of Repeated Intratumoral and Cervical Perilymphatic Lerapolturev Injections Versus Lomustine in Recurrent Glioblastoma (GBM)
Status: Not yet recruiting, Estimated PCD: 2029-02-01
Product
Lerapolturev
Clinical trial
Phase I/II Dose Escalation Trial of Radiodynamic Therapy (RDT) With 5-Aminolevulinic Acid in Patients With First Recurrence of Glioblastoma
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Gliolan
Clinical trial
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Product
UCPVax
Clinical trial
Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Study of Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE).
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Daratumumab
Clinical trial
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Surgical "Window-of-Opportunity" and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Product
Veliparib
Clinical trial
Targeting Myeloid Derived Suppressor Cells in Recurrent Glioblastoma: Phase 0/1 Trial of Low Dose Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2019-03-25
Clinical trial
Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma
Status: Recruiting, Estimated PCD: 2025-05-01
Product
Cetuximab
Product
Mannitol
Clinical trial
Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
Status: Withdrawn, Estimated PCD: 2024-12-31
Drug
ONC201
Clinical trial
A Phase 0/2 Study of Abemaciclib in Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Abemaciclib
Clinical trial
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Neratinib
Product
QBS10072S
Clinical trial
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Phase 1, Open-label Study Evaluating the Safety and Feasibility of CART-EGFR-IL13Ra2 Cells in Patients With EGFR-Amplified Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-19
Product
CART-EGFR-IL13Ra2
Clinical trial
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas
Status: Active (not recruiting), Estimated PCD: 2022-02-21
Product
Carboxylesterase-expressing Allogeneic Neural Stem Cells
Drug
FOLFOXIRI
Clinical trial
Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab
Status: Terminated, Estimated PCD: 2024-04-24
Clinical trial
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-10-27
Product
Binimetinib
Product
Research Bloods
Product
Tumor Tissue
Clinical trial
A Randomized, Double-blind, Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Cannabidiol
Drug
Varlilumab
Clinical trial
Window of Opportunity Assessment of [Fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)
Status: Recruiting, Estimated PCD: 2027-09-22
Product
Trastuzumab deruxtecan
Clinical trial
A Phase I Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Product
Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
Product
Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary
Clinical trial
Phase I Clinical Trial on Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma
Status: , Estimated PCD: 2023-11-17
Clinical trial
A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2022-05-13
Product
Personalized neoantigen DNA vaccine
Product
Plasmid encoded IL-12
Clinical trial
A Phase II Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
Status: Completed, Estimated PCD: 2014-10-29
Product
PX-866
Clinical trial
A Phase II Study of Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2024-07-01
Product
rQNestin
Clinical trial
An Open, Single-arm, Phase 1 Study to Evaluate the Safety/Preliminary Effectiveness and Determine the Maximal Tolerated Dose of B7-H3-targeting CAR-T Cell Therapy in Treating Recurrent Glioblastomas
Status: Recruiting, Estimated PCD: 2024-12-31
Product
B7-H3-targeting CAR-T cells
Clinical trial
A Phase I Clinical Trial With a Window-of-Opportunity Component of Engineered NK Cells Containing Deleted TGF-ßR2 and NR3C1 in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2026-01-31
Product
Cord Blood-derived Expanded Allogeneic Natural Killer Cells
Clinical trial
Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2016-11-16
Product
Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
Clinical trial
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme
Status: Terminated, Estimated PCD: 2022-01-13
Product
Disulfiram
Clinical trial
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 0/Ia Study of BI 907828 (Brigimadlin) Concentrations in Brain Tissue and a Non-randomized Open-label, Dose Escalation Study of BI 907828 in Combination With Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2027-11-01
Product
BI 907828
Clinical trial
A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2021-10-18
Drug
mFOLFOX6
Product
Vorinostat
Clinical trial
A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)
Status: Completed, Estimated PCD: 2017-09-01
Product
SL-701
Product
Imiquimod
Clinical trial
2014062501
Status: Completed, Estimated PCD: 2020-03-01
Clinical trial
Targeting Transsulfuration Via Suppression of Thyroid Hormone Signaling in Progressive Glioblastoma: Phase 2 and Pharmacodynamic Trial of Methimazole in Patients With Progressive Glioblastoma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Methimazole
Clinical trial
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Status: Recruiting, Estimated PCD: 2026-02-28
Product
Atorvastatin
Clinical trial
A Phase I De-Escalation Study of Dexamethasone With Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2024-11-29
Drug
Azeliragon
Product
Dexamethasone
Clinical trial
Combination of Checkpoint Inhibition and IDO1 Inhibition Together With Standard Radiotherapy or Chemoradiotherapy in Newly Diagnosed Glioblastoma. A Phase 1 Clinical and Translational Trial
Status: Active (not recruiting), Estimated PCD: 2024-02-22
Product
IDO1 Inhibitor BMS-986205
Clinical trial
Phase I Trial of DNA-PK Inhibitor (M3814) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated Glioblastoma
Status: Recruiting, Estimated PCD: 2025-10-30
Product
Peposertib
Clinical trial
An Exploratory Study on Camrelizumab Combined With Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)
Status: , Estimated PCD: 2023-12-31
Product
Camrelizumab + Bevacizumab
Clinical trial
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
Status: Withdrawn, Estimated PCD: 2023-08-29
Product
F18 Fluciclovine
Clinical trial
A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Product
18F-FluorThanatrace
Clinical trial
Multispectral and Bimodal Fluorescent Guided Surgery (FGS) of High-grade Glioma for Refining Margin Assessment: A Phase 1 Dose Finding Study Using Cetuximab-IRDye800CW Combined With 5-ALA.
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Cetuximab-IRDye800
Clinical trial
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
Status: Completed, Estimated PCD: 2022-02-23
Product
Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Clinical trial
A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2022-06-03
Clinical trial
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2025-06-01
Drug
Tocilizumab
Clinical trial
A Phase II Clinical Study of GC1118 in Recurrent Glioblastoma Patients With High Epidermal Growth Factor Receptor (EGFR) Amplification
Status: Completed, Estimated PCD: 2018-09-08
Product
GC1118
Clinical trial
Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study
Status: Completed, Estimated PCD: 2016-04-25
Product
Autologous Dendritic Cell Vaccination
Clinical trial
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
Status: Active (not recruiting), Estimated PCD: 2023-12-18
Product
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Product
IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Clinical trial
Efficacy and Safety of Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma: A Multi-center Phase II Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
Elemene
Clinical trial
A Phase 2a Trial of Immune Modulation in Combination With Ultrasound-mediated Blood Brain Barrier Opening in Patients With Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2026-05-01
Product
Balstilimab
Drug
Botensilimab
Product
Liposomal Doxorubicin
Clinical trial
A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor
Status: Recruiting, Estimated PCD: 2024-01-26
Drug
Plerixafor
Clinical trial
A Single Center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of Neoadjuvant and Adjuvant Pembrolizumab on Top of Standard Chemo-Radiotherapy (Stupp Protocol) in Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme (GBM).
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase I Study of Metronomic Temozolomide With Abexinostat (PCI-24781) for Patients With Recurrent High Grade Glioma
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 0, Single-center, Open-label, Dose-escalating Trial Using Super-selective Intra-arterial Infusion of a Single Dose of Temsirolimus for the Treatment of Recurrent High-grade Glioma
Status: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Phase I-II Study Evaluating HSV-tK + VALACYCLOVIR GENE THERAPY Combination With Radiotherapy and Chemotherapy for Newly Diagnosed Anaplastic Astrocytoma and Glioblastoma Multiforme.
Status: Recruiting, Estimated PCD: 2023-12-31
Product
ADV/HSV-tk
Clinical trial
Phase I/II Trial of Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 0/I Dose Escalation Study of Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
Status: Recruiting, Estimated PCD: 2024-10-01
Drug
mycophenolate mofetil
Clinical trial
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2020-10-31
Product
Unpulsed DCs
Clinical trial
Pilot Study of Sonodynamic Therapy With 5-ALA for the Treatment of Recurrent Glioblastoma Using Neuronavigation-Guided Low-Intensity Focused Ultrasound
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)
Status: Active (not recruiting), Estimated PCD: 2025-11-10
Clinical trial
A Phase II Trial of Tumor Treating Fields (TTFields) Concomitant With Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-07-20
Product
TTFields and SRS
Clinical trial
A Phase II Randomized Controlled Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma
Status: Withdrawn, Estimated PCD: 2023-11-10
Product
Chloroquine
Clinical trial
A Phase 0/1b, Single Center, Clinical Trial With an Expansion Phase of AZD1390 Plus Fractionated Radiotherapy in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Status: Recruiting, Estimated PCD: 2024-07-01
Drug
AZD1390
Clinical trial
Phase I Trial Combining Sulfasalazine and Gamma Knife Radiosurgery for Recurrent Glioblastoma
Status: Completed, Estimated PCD: 2022-10-14
Clinical trial
A Phase II Study of the Anti-GITR Agonist INCAGN1876 and the PD-1 Inhibitor INCMGA00012 in Combination With Stereotactic Radiosurgery in Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2022-09-08
Product
INCMGA00012
Product
INCAGN01876
Product
SRS
Clinical trial
A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells Combined With Checkpoint Inhibition for Patients With Resectable Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-07-31
Drug
Lurbinectedin
Clinical trial
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma: a Phase II Study
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Autologous Dendritic Cells vaccine
Clinical trial
Efficacy and Safety of Superselective Cerebral Arterial Infusion of Bevacizumab Combined With Intrathecal Injection of Tislelizumab in the Treatment of Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
Pilot Study Testing Feasibility of Individualized Therapy for Recurrent Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2023-11-30
Product
Individualized therapy
Clinical trial
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma
Status: Active (not recruiting), Estimated PCD: 2020-08-27
Product
Sorafenib
Product
Valproic acid
Product
Sildenafil citrate
Clinical trial
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma.
Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Radiotherapy With or Without Temozolomide and in Recurrent Glioblastoma as Single Agent
Status: Recruiting, Estimated PCD: 2025-07-28
Product
[177Lu]Lu-DOTA-TATE
Product
[68Ga]Ga-DOTA-TATE
Clinical trial
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Status: Completed, Estimated PCD: 2022-12-20
Product
HSPPC-96
Clinical trial
Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination With Temozolomide in Patients With Malignant Gliomas
Status: Active (not recruiting), Estimated PCD: 2018-10-18
Clinical trial
Loc3CAR: Locoregional Delivery of B7-H3-specific Chimeric Antigen Receptor Autologous T Cells for Pediatric Patients With Primary CNS Tumors
Status: Recruiting, Estimated PCD: 2028-03-01
Product
B7-H3-CAR T cells
Clinical trial
PH Weighted Chemical Exchange Saturation Transfer Based Surgical Resections of Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase 2 Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Sintilimab + Bevacizumab + Temozolomide
Clinical trial
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Open Label Randomized Phase II/III Trial of Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy (DEN-STEM)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Dendritic cell immunization
Product
Adjuvant temozolomide
Clinical trial
Phase I/II Study of AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Polysiloxane Gd-Chelates based nanoparticles
Clinical trial
Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
Status: Terminated, Estimated PCD: 2020-01-31
Clinical trial
A Phase Ib Clinical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters Following Neoadjuvant Anti-PD-1 (Nivolumab), or the Combination of Anti-PD-1 Plus Anti-CTLA-4 (Nivolumab Plus Ipilimumab) in Patients With Surgically Accessible Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Nivolumab-Placebo
Product
Ipilimumab-Placebo
Clinical trial
Pembrolizumab for Newly Diagnosed Glioblastoma: a Prospective, Open-label, Single-arm, Multicenter Phase II Study
Status: Active (not recruiting), Estimated PCD: 2026-04-30
Clinical trial
Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2025-03-01
Product
TN-TC11G
Clinical trial
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Status: , Estimated PCD: 2025-05-31
Clinical trial
Creating Metabolic Vulnerabilities in Patients With EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR With Osimertinib
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Drug
Osimertinib
Clinical trial
Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Status: Completed, Estimated PCD: 2022-08-31
Product
Bavituximab
Clinical trial
Phase II Trial O6-benzylguanine(BG) and Temozolomide(TMZ) Therapy of Glioblastoma Multiforme (GBM) With Infusion of Autologous P140K MGMT+Hematopoietic Progenitors to Protect Hematopoiesis
Status: Recruiting, Estimated PCD: 2024-06-01
Product
P140K-MGMT
Product
O6-benzylguanine
Drug
carmustine
Clinical trial
Phase I Study -To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T Cell Therapy in CD70+ Adult GBM
Status: Recruiting, Estimated PCD: 2027-12-01
Product
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Clinical trial
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas: A Phase 0 Clinical Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Ketoconazole
Clinical trial
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Product
Vγ9Vδ2 T cell
Clinical trial
Phase II Trial of Niraparib in Patients With Recurrent Glioma
Status: Terminated, Estimated PCD: 2023-11-14
Clinical trial
Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Status: Active (not recruiting), Estimated PCD: 2024-10-24
Clinical trial
Treatment of Adults With Newly Diagnosed Glioblastoma With Partial Brain Radiation Therapy Plus Temozolomide and Chloroquine Followed by Tumor Treating Fields Plus Temozolomide and Chloroquine -- A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2025-04-27
Clinical trial
Prospective Study of Stereotactic Radiosurgery Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-line Chemotherapy
Status: Completed, Estimated PCD: 2016-12-01
Drug
Cisplatin
Clinical trial
Pilot Study of Spectroscopic MRI-Guided, Dose-Escalated Radiation Therapy for Newly-Diagnosed Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2025-01-04
Clinical trial
Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Recurrent Glioblastoma
Status: Completed, Estimated PCD: 2021-06-02
Clinical trial
Phase II Trial of Vaccination With Lysate-loaded, Mature Dendritic Cells Integrated Into Standard Radiochemotherapy in Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2026-11-06
Product
Autologous, tumor lysate-loaded, mature dendritic cells (DC)
Product
Standard Therapy
Clinical trial
Cytokine Microdialysis For Real Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
Status: Completed, Estimated PCD: 2023-04-21
Product
BMS-986016
Clinical trial
A Single Patient Compassionate Use Clinical Trial for the Use of L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment Diffuse Midline Glioma, H3 K27/28-altered (DMG), Including Diffuse Intrinsic Pontine Glioma (DIPG)
Status:
Product
S-Gboxin
Clinical trial
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Posaconazole
Clinical trial
A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
Status: Active (not recruiting), Estimated PCD: 2022-10-31
Product
Fimepinostat
Clinical trial
A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma
Status: Active (not recruiting), Estimated PCD: 2025-01-31
Product
Autologous Tumor Lysate-pulsed DC Vaccination
Product
Tumor lysate-pulsed DC vaccination + 0.2% resiquimod
Clinical trial
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma: Comparison of Two Established Schedules
Status: Active (not recruiting), Estimated PCD: 2028-12-01
Clinical trial
A Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Hypofractionated Re-irradiation and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs
Status: Completed, Estimated PCD: 2014-04-01
Clinical trial
A Phase II Study Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (PRORADGLIO Study)
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Concurrent Chemotherapy
Clinical trial
Pilot Trial of Temsirolimus and Perifosine in Recurrent/Progressive Malignant Gliomas
Status: Completed, Estimated PCD: 2017-10-27
Product
Perifosine
Clinical trial
A Single-Dose Study of Orally Administrated Defactinib or VS-6766 in Patients With Glioblastoma
Status: Recruiting, Estimated PCD: 2024-10-31
Drug
Avutometinib
Drug
Defactinib
Product
Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
Clinical trial
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Status: Completed, Estimated PCD: 2017-03-31
Product
Alisertib
Clinical trial
The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Clindamycin
Product
Triamcinolone Acetonide
Clinical trial
Feasibility Study of a Static Magnetic and Electric Field Device in Adults With Recurrent Glioblastoma and Their Partners
Status: Withdrawn, Estimated PCD: 2026-08-01
Clinical trial
Safety、Tolerability、Pharmacokinetics and Initial Efficacy of Recombinant L-IFN Adenovirus Injection in the Treatment of Recurrent Glioblastoma：an Open-label, Single-arm, Single-center, Multi-dose Investigator-initiated Clinical Trial
Status: Recruiting, Estimated PCD: 2024-06-12
Product
Recombinant L-IFN adenovirus
Clinical trial
A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Personalized NeoAntigen Vaccine
Product
PCI 24781
Clinical trial
Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma
Status: Completed, Estimated PCD: 2021-02-27
Product
CART-EGFRvIII T cells
Clinical trial
Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma
Status: Terminated, Estimated PCD: 2023-04-05
Product
DNX-2440
Clinical trial
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
Navtemadlin
Clinical trial
A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma
Status: Recruiting, Estimated PCD: 2026-12-01
Product
FDA approved drugs panel
Product
Intra-arterial Mannitol
Clinical trial
Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.
Status: Terminated, Estimated PCD: 2019-12-12
Product
Folinic acid
Clinical trial
Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab
Status: Not yet recruiting, Estimated PCD: 2024-02-28
Product
cadonilimab
Clinical trial
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
A Phase I/II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Status: Terminated, Estimated PCD: 2020-05-29
Clinical trial
A Phase I Study to Investigate the Safety, Pharmacokinetic Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Di-Agnosed MGMT-Promoter Unmethylated Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2024-12-30
Product
Tinostamustine
Clinical trial
Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma: A Single-arm, Prospective Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2027-12-30
Drug
PD-1 antibody
Clinical trial
A Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Primary Brain Tumors
Status: Recruiting, Estimated PCD: 2023-09-21
Product
Microdevice
Product
111In-labeled DCs
Product
Basiliximab
Clinical trial
A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Status: Recruiting, Estimated PCD: 2030-08-31
Drug
R-CHOP
Clinical trial
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas
Status: Terminated, Estimated PCD: 2015-12-01
Product
AXL1717
Clinical trial
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Safety and Tolerability of Tumor Treating Fields (TTFields) Combined With Chemoradiation in Newly Diagnosed Glioblastoma (Unity)
Status: Terminated, Estimated PCD: 2021-02-24
Clinical trial
Multicenter, Open Label, Phase I Study of Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Product
NK-92/5.28.z
Product
Ezabenlimab
Clinical trial
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Product
Lorlatinib
Product
AB122
Product
AB154
Clinical trial
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Status: Terminated, Estimated PCD: 2017-04-03
Clinical trial
Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Drug
Tiragolumab
Clinical trial
Restrictive Use of Dexamethasone in Glioblastoma
Status: Recruiting, Estimated PCD: 2025-04-01
Drug
lenalidomide
Clinical trial
Response Assessment to Pembrolizumab With Standard of Care Therapy in Glioblastoma Using Ferumoxytol Steady State Imaging- A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
Status: Recruiting, Estimated PCD: 2026-11-21
Drug
Docetaxel
Product
Stupp Protocol
Clinical trial
Reirradiation (Re-RT) and Niraparib (NIRA) in Patients With Recurrent Glioblastoma (rGBM)
Status: Withdrawn, Estimated PCD: 2023-10-13
Clinical trial
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Status: Recruiting, Estimated PCD: 2027-09-30
Product
Trametinib
Clinical trial
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion
Status: Recruiting, Estimated PCD: 2026-10-23
Product
Erdafitinib
Clinical trial
Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma and as a Single Agent in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2026-05-04
Product
[177Lu]Lu-NeoB
Product
[68Ga]Ga-NeoB
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/21477
Product
AV-GBM-1 + GM-CSF
Product
DC1 Vaccine
Product
MEDI0562
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20252
Product
sequential bortezomib and temozolomide
Clinical trial
A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects
Status: Completed, Estimated PCD: 2022-09-23
Product
Bemcentinib
Clinical trial
A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Activated T cells